- Home
- OBIO
as 11-15-2024 4:00pm EST
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HOPE |
| Market Cap: | 200.1M | IPO Year: | N/A |
| Target Price: | $15.75 | AVG Volume (30 days): | 57.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.22 - $11.69 | Next Earning Date: | 11-12-2024 |
| Revenue: | $2,647,000 | Revenue Growth: | -26.49% |
| Revenue Growth (this year): | 7.68% | Revenue Growth (next year): | 110.40% |
Stock Insider Trading Activity of Orchestra BioMed Holdings Inc. (OBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sherman Darren | OBIO | See Remarks | Sep 9 '24 | Sell | $5.40 | 13,708 | $73,946.16 | 765,787 | |
| Fain Eric S | OBIO | Director | Sep 6 '24 | Sell | $5.47 | 5,600 | $30,666.00 | 41,210 | |
| Sherman Darren | OBIO | See Remarks | Sep 4 '24 | Sell | $5.87 | 20,617 | $120,954.90 | 765,787 |
Latest Orchestra BioMed Holdings Inc. News
OBIO Breaking Stock News: Dive into OBIO Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Orchestra BioMed Holdings Third Quarter 2024 Earnings: Beats Expectations
Simply Wall St.
3 days ago
We Think Orchestra BioMed Holdings (NASDAQ:OBIO) Needs To Drive Business Growth Carefully
Zacks
5 days ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
5 days ago
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
10 days ago
Orchestra BioMed to Participate in Jefferies London Healthcare Conference
Zacks
a month ago
Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 09/27/2024
Zacks
3 months ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
Compare OBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OBIO Orchestra BioMed Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.